(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 ...

This was the stock's second consecutive day of gains.

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

The top winners were recognized during two award ceremonies: the Special Awards on May 15 and the Grand Awards Ceremony on May 16. In total, more than $9 million in awards and scholarships were ...

White & Case secures $405M jury win for Regeneron in antitrust case, with Amgen found liable for anti-competitive bundling ...

The most significant addition was Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with 114,880 shares, accounting for 3.88% of ...

Moreover, previous studies have suggested that more conservative options can be successfully used for low-risk, early-stage cervical cancer. The SHAPE trial, for example, showed that simple ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

Adam Kovalčík, 19,receives $100,000 Top Award forhisdevelopment of amedicinethatcan stopviruses from copying genesandcontrolling infectionsat the world’s largest pre-college STEM competition in ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Novo Nordisk's CEO, who led its boom driven by obesity and diabetes medications only to see that success stall, is stepping ...